文献速递骨软组织肉瘤与黑色素瘤

BRAF V600E/K突变状态与既往BRAF/MEK抑制剂治疗对帕博利珠单抗疗效的关联:3项临床试验汇总分析

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
PubMed 文献 · JAMA Oncol · 2020-01-01

该研究为3项临床试验(KEYNOTE-001、002、006)的汇总事后亚组分析,纳入1558例晚期黑色素瘤患者,评估BRAF野生型或V600E/K突变状态及既往BRAF±MEK抑制剂治疗与帕博利珠单抗疗效的关联。结果显示总体客观缓解率38.3%,4年无进展生存率22.0%,4年总生存率36.9%;BRAF野生型与突变型患者疗效相近,但既往接受BRAF±MEK抑制剂治疗者疗效较差。结论支持帕博利珠单抗用于晚期黑色素瘤 regardless of BRAF状态或既往靶向治疗。

要点

  • 帕博利珠单抗在BRAF野生型和V600E/K突变型晚期黑色素瘤中均显示疗效。
  • 既往接受BRAF±MEK抑制剂治疗的患者客观缓解率和生存率较低。
  • 结果支持帕博利珠单抗用于晚期黑色素瘤,不受BRAF状态或既往靶向治疗影响。

核心结论

  • 帕博利珠单抗可用于晚期黑色素瘤,无论BRAF V600E/K突变状态或是否接受过既往BRAF±MEK抑制剂治疗。

研究设计与样本

  • 研究为3项多国多中心试验(KEYNOTE-001、KEYNOTE-002、KEYNOTE-006)的汇总事后亚组分析。
  • 纳入1558例已知BRAF V600E/K状态的晚期黑色素瘤成人患者,均接受帕博利珠单抗治疗。
  • 帕博利珠单抗给药方案包括2 mg/kg每3周、10 mg/kg每2周或10 mg/kg每3周。

主要发现

  • 总体客观缓解率为38.3%(596/1558),4年无进展生存率为22.0%,4年总生存率为36.9%。
  • BRAF野生型(n=1124)与BRAF V600E/K突变型(n=434)患者的客观缓解率分别为39.8%(n=447)和34.3%(n=149)。
  • BRAF野生型与突变型患者的4年无进展生存率分别为22.9%和19.8%,4年总生存率分别为37.5%和35.1%。
  • 既往接受BRAF±MEK抑制剂治疗(n=271)与未接受(n=163)的BRAF突变患者,客观缓解率分别为28.4%(n=77)和44.2%(n=72)。
  • 既往接受与未接受BRAF±MEK抑制剂治疗者的4年无进展生存率分别为15.2%和27.8%,4年总生存率分别为26.9%和49.3%。

临床怎么用

  • 晚期黑色素瘤患者使用帕博利珠单抗时,无需因BRAF V600E/K突变状态或既往BRAF±MEK抑制剂治疗史而排除。
  • 对于既往接受过BRAF±MEK抑制剂治疗的患者,应知晓其接受帕博利珠单抗的缓解率和长期生存率可能较低。

局限性

  • 本研究为事后亚组分析,非预设主要分析。
  • 既往治疗亚组间基线特征不均衡,既往接受BRAF±MEK抑制剂治疗者预后因素更差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The optimal sequencing of immune checkpoint inhibitors and targeted therapy for BRAF V600E/K-mutant melanoma is not well established. OBJECTIVE: To assess the association of BRAF wild-type (WT) or BRAF V600E/K-mutant status and BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi) therapy with response to pembrolizumab. DESIGN, SETTING, AND PARTICIPANTS: This study is a post hoc subgroup analysis of pooled data from 3 multinational, multisite studies: KEYNOTE-001 (data cutoff September 1, 2017), KEYNOTE-002 (data cutoff May 30, 2018), and KEYNOTE-006 (data cutoff December 4, 2017). Patients included in this analysis were adults with advanced melanoma and known BRAF V600E/K tumor status who had received pembrolizumab. INTERVENTIONS: Patients received pembrolizumab in dosages of 2 mg/kg every 3 weeks, 10 mg/kg every 2 weeks, or 10 mg/kg every 3 weeks. MAIN OUTCOMES AND MEASURES: End points were objective response rate (ORR) and progression-free survival (PFS) assessed by Response Evaluation Criteria in Solid Tumors, version 1.1, and overall survival (OS). Objective response rates, 4-year PFS, and OS rates were compared in the following patient subgroups: BRAF WT vs BRAF V600E/K-mutant melanoma and BRAF V600E/K-mutant melanoma with vs without previous treatment with BRAFi with or without MEKi therapy. RESULTS: The overall study population (N = 1558) included 944 men (60.6%) and 614 women (39.4%). The mean (SD) age was 60.0 years (14.0). The ORR was 38.3% (596/1558), 4-year PFS rate was 22.0%, and 4-year OS rate was 36.9%. For patients with BRAF WT (n = 1124) and BRAF V600E/K-mutant melanoma (n = 434), ORR was 39.8% (n = 447) and 34.3% (n = 149), 4-year PFS rate was 22.9% and 19.8%, and 4-year OS rate was 37.5% and 35.1%, respectively. Patients with BRAF V600E/K-mutant melanoma who had (n = 271) vs had not (n = 163) previously received BRAFi with or without MEKi therapy had baseline characteristics with worse prognosis; ORR was 28.4% (n = 77) and 44.2% (n = 72), 4-year PFS rate was 15.2% and 27.8%, and 4-year OS rate was 26.9% and 49.3%, respectively. CONCLUSIONS AND RELEVANCE: Results of this subgroup analysis support the use of pembrolizumab for treatment of advanced melanoma regardless of BRAF V600E/K mutation status or receipt of prior BRAFi with or without MEKi therapy.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Puzanov I, Ribas A, Robert C, et al. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. JAMA Oncol. 2020. PMID: 32672795. doi:10.1001/jamaoncol.2020.2288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。